Comprehensive Menopause Support
Published
Introduction
This comprehensive protocol embraces a whole-person approach to menopause, addressing a range of symptoms beyond the typical hot flashes. The protocol features targeted ingredients to support various aspects of menopausal health: Amarasate® for weight management, and Maca-GO® for hormonal balance, libido, and hot flashes. Additionally, collagen is included for joint and muscle health, while calcium and vitamin D support bone health. Magnesium aids in sleep, stress reduction, and musculoskeletal well-being. This holistic approach ensures that common but often overlooked symptoms are effectively managed.
While the ingredients in this protocol have demonstrated benefits, research specifically targeting peri- and postmenopausal women is still evolving. This protocol is designed with the broader goal of supporting menopausal health, incorporating ingredients that may offer valuable support even as research in this specific population continues to develop.
In addition to this comprehensive approach, Fullscript also offers practitioners an Essential Menopause Support protocol. The essential version is designed to support uncomplicated menopausal cases, with a focus on vasomotor symptoms like hot flashes and night sweats. It includes key evidence-based ingredients such as black cohosh, chaste tree, rhubarb, ashwagandha, and saffron.
Providers may choose to use the essential protocol on its own or layer it with this comprehensive protocol to tailor care based on the range and complexity of symptoms they are looking to address.
Ingredients
Amarasate®
Dosing: 125–250 mg, twice per day (Walker 2024)
- Significantly reduced hunger (30%) and food cravings (40%) in women during a 24-hour water-only fast; both high-dose (500 mg) and low-dose (250 mg) treatments, administered 16 and 20 hours into the fast, led to a significant reduction in appetite and cravings compared to placebo
- Decreased post-fast ad libitum energy intake by up to 14.5% in women (Walker 2024)
- Reduced pre-meal cravings for savory foods and post-meal cravings for sugary foods in women (Walker 2024)
- Increased preprandial ghrelin and postprandial levels of CCK, GLP-1 (600%), and PYY (400%), while reducing postprandial insulin, glucose-dependent insulinotropic peptide (GIP), and pancreatic polypeptide responses without affecting blood glucose levels; this modulation of hormone levels suggests enhanced satiety signals and improved metabolic control without causing hypoglycemia (Walker 2024)
Maca-GO®
Dosing: 1 g twice per day for three months (Meissner 2006 a)
- Reduced menopausal symptoms by 84% in early postmenopausal women and 74–82% in perimenopausal women (Meissner 2006 a)(Meissner 2006 c)
- Significantly decreased FSH levels while simultaneously increasing LH, estrogen, and progesterone levels in early postmenopausal women after eight months of supplementation (Meissner 2005)
- Increased bone density markers in early-postmenopausal women after four months of supplementation (Meissner 2006 b)
- Increased HDL cholesterol levels, reduced LDL cholesterol levels and triglycerides, and helped maintain a healthy body weight in early postmenopausal women after four months of supplementation (Meissner 2006 b)
- Significantly reduced hot flashes, night sweats, vaginal dryness, and nervousness, and enhanced libido, mood, energy levels, and concentration in perimenopausal women after four months of supplementation (Meissner 2006 c)
Calcium and Vitamin D
Dosing: >1,000 mg of calcium per day and >800 IU of vitamin D per day, ongoing
- Hypertension: >800 IU per day of vitamin D (Golzarand 2016) and >1,000 mg of calcium (Cormick 2015) decreased SBP (~1.5–4 mmHg and 1.14 mmHg, respectively) and DBP (~1.2–2.2 mmHg and 0.71 mmHg, respectively).
- Osteoporosis and fractures: A meta-analysis including eight randomized controlled trials (RCTs) with 30,970 participants found that calcium and vitamin D supplementation reduced the relative risk of total fracture by 15% and hip fracture by 30% in community-dwelling and institutionalized middle-aged to older adults. (Weaver 2016)
Vaginal atrophy: 1,000 IU of vitamin D as a vaginal suppository, every night before bed for eight weeks, to postmenopausal women decreased vaginal pH and genitourinary atrophy symptom scores such as pain, dryness, and paleness and increased Vaginal Maturation Index and the number of superficial cells. (Keshavarzi 2019)(Rad 2015)
Collagen
Dosing: Variable depending on collagen type, ongoing
- Hypertension: 2.9 g per day of chicken-derived collagen hydrolysate for 12 weeks may decrease SBP and increase serum nitric oxide (NO). ((Kouguchi 2013)
- Osteoarthritis: 2 g per day of chicken-derived hydrolyzed collagen type II BioCell® and 40 g per day of chicken-derived cartilage, undenatured type II collagen UC-II® for 70–180 days, respectively, may decrease visual analog scale (VAS) pain, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores, and joint stiffness. (Lugo 2016)(Schauss 2012)
- Osteoporosis: 5 g per day of bioactive collagen peptides, Fortibone®, for 12 months may increase spine and neck bone mineral density. (König 2018)
Skin aging: 2.5 g per day of porcine-derived bioactive collagen peptides, Verisol® type I collagen, for four weeks may decrease eye wrinkle volume by 20% and increase procollagen type I and elastin content by 65%. (Proksch 2013a)(Proksch 2013b)
Magnesium
Dosing: 320 mg to >1 g per day (depending on the form) for a minimum of eight weeks
- Depression: Postmenopausal women with depressive symptoms exhibit notably lower magnesium levels (14.28 ± 2.13 mg/L) than those without depressive symptoms (16.30 ± 3.51 mg/L). (Szkup 2016) Supplementing with 320–500 mg of magnesium per day for eight weeks may decrease the risk for depression and Beck scores. (Li 2017)(Rajizadeh 2017)
- Hypertension: 365–450 mg of elemental magnesium for 1–6 months decreased SBP (-4.18 mmHg) and DBP (-2.27 mmHg) in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases. (Dibaba 2017)
- Osteoporosis: 1,830 mg of magnesium citrate per day for 30 days in postmenopausal women decreased serum intact parathyroid hormone (iPTH) and urinary deoxypyridinoline and increased serum osteocalcin. (Aydin 2009)
- Sleep issues: 500 mg of magnesium oxide twice daily for eight weeks increased sleep time, sleep efficiency, and serum melatonin levels and decreased sleep onset latency and serum cortisol levels. (Abbasi 2012) Magnesium glycinate has a greater absorption rate than magnesium oxide and could provide similar benefits at a lower dose with fewer side effects (24% vs. 4%). (Firoz 2001)(Schuette 1994)
Evidence Rating
Clinical guide development in integrative medicine is not typically a simple process. Individuals require individualized care, and what works for one patient may not work for another.
As a result, the Fullscript Medical Advisory team advises using an evidence-informed approach to protocol development. To simplify this process for healthcare providers, we have assembled a sampling of evidence-based treatment approaches that providers can use as a starting point when developing individualized treatment plans.
To establish these clinical guides, we first developed a Rating Scale to assess the rigor of the evidence supporting a specific intervention's therapeutic effect. All clinical guides were developed using only A through D-quality evidence.
Authors & medical reviewers

Natacha Montpellier, ND
Lead, Clinical Science Liaison, FullscriptDr. Natacha Montpellier, ND, is a registered naturopathic doctor in Ontario, Canada. She also serves as a Lead Clinical Science Liaison on Fullscript’s Medical Advisory team.

Christopher Knee, ND, MSc
Manager, Clinical Research & Decision SupportDr. Christopher Knee is a naturopathic doctor and clinical researcher from Ottawa, Canada, recognized as a subject matter expert in clinical nutrition, dietary supplements, treatment adherence, and whole person care. In addition to part-time practice, he serves as Head of Clinical Research and Decision Support on Fullscript’s Medical Innovation Team.